The Clinical Sequencing Evidence-Generating Research (CSER) consortium is a national multi-site research program funded by the National Human Genome Research Institute (NHGRI), the National Cancer Institute (NCI) and the National Institute on Minority Health and Health Disparities (NIMHD).

Prioritizing engagement of traditionally underrepresented populations in genomics research, CSER’s six clinical sites seek to study the effectiveness of integrating genome sequencing into the clinical care of diverse and medically underserved individuals. CSER’s research goals include measuring sequencing’s clinical utility through patient and familial responses to genomic testing and evaluating patient-provider-laboratory interactions that influence the use of sequencing. Drawing from the expertise of clinicians, scientists, ethicists, bioinformaticians, economists, and legal scholars, CSER is poised to develop and share best practices in areas such as the discovery and interpretation of genomic variants, return of results, healthcare utilization, health outcomes and metrics, and the ethical, legal, and social implications of sequencing in diverse populations.

Clinical Sequencing Evidence-Generating Research (CSER) Sites:

  • CHARM, Kaiser Permanente Northwest
  • KidsCanSeq, Baylor College of Medicine
  • NC GENES 2, University of North Carolina, Chapel Hill 
  • NYCKidSeq, Icahn School of Medicine at Mount Sinai
  • P3EGS, University of California, San Francisco
  • South-Seq, HudsonAlpha Institute for Biotechnology
  • CSER Coordinating Center, University of Washington, Seattle